Cargando…

Effect of quercetin on oxidative stress and liver function in beta-thalassemia major patients receiving desferrioxamine: A double-blind randomized clinical trial

BACKGROUND: Blood transfusion therapy is lifesaving for beta-thalassemia major patients, yet it indirectly causes complications such as oxidative stress and liver dysfunction. In the present study, we investigated the effect of quercetin supplementation on oxidative stress and liver function in beta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sajadi Hezaveh, Zohreh, Azarkeivan, Azita, Janani, Leila, Shidfar, Farzad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856539/ https://www.ncbi.nlm.nih.gov/pubmed/31741663 http://dx.doi.org/10.4103/jrms.JRMS_911_18

Ejemplares similares

Associates of poor physical and mental health-related quality of life in beta thalassemia-major/intermedia
por: Azarkeivan, Azita, et al.
Publicado: (2009)

Prospective comparison on cardiac iron by MR in thalassemia major patients treated with combination deferipron-desferrioxamine versus deferipron and desferrioxamine in monoterapy
por: Pepe, Alessia, et al.
Publicado: (2011)

Contrast Sensitivity in Patients with Beta-Thalassemia Major and Sickle Cell Disease Under Regular Transfusions and Treatment with Desferrioxamine
por: Gorezis, Spyridon, et al.
Publicado: (2010)

The effect of synbiotic supplementation on hypothyroidism: A randomized double-blind placebo controlled clinical trial
por: Ramezani, Majid, et al.
Publicado: (2023)

A T2* MRI prospective survey on heart iron in thalassemia major patients treated with sequential deferiprone-desferrioxamine versus deferipron and desferrioxamine in monotherapy
por: Pepe, Alessia, et al.
Publicado: (2011)

A Large Cohort Study of Genotype and Phenotype Correlations of Beta- Thalassemia in Iranian Population
por: Maryami, Fereshteh, et al.
Publicado: (2015)

Economic Burden of Thalassemia Major in Iran, 2015
por: Esmaeilzadeh, Firooz, et al.
Publicado: (2016)

An international survey of patients with thalassemia major and their views about sustaining life-long desferrioxamine use
por: Ward, Alexandra, et al.
Publicado: (2002)

Hepcidin gene polymorphisms and iron overload in β-thalassemia major patients refractory to iron chelating therapy
por: Zarghamian, Parinaz, et al.
Publicado: (2020)

Renal Hemosiderosis among Iranian Transfusion Dependent β-Thalassemia Major Patients
por: Hashemieh, Mozhgan, et al.
Publicado: (2017)

Quality of life in patients with thalassemia major
por: Ansari, Sh, et al.
Publicado: (2014)

Survival analysis of thalassemia major patients using Cox, Gompertz proportional hazard and Weibull accelerated failure time models
por: Bakhshi, Enayatollah, et al.
Publicado: (2017)

A T2* MRI prospective survey on heart iron in thalassemia major patients treated with sequential deferipron-desferrioxamine versus deferasirox
por: Pepe, Alessia, et al.
Publicado: (2011)

A T2* MRI prospective survey on heart iron in thalassemia major patients treated with deferasirox versus deferiprone and desferrioxamine in monotherapy
por: Pepe, Alessia, et al.
Publicado: (2011)

Estimates of the effect on hepatic iron of oral deferiprone compared with subcutaneous desferrioxamine for treatment of iron overload in thalassemia major: a systematic review
por: Caro, J Jaime, et al.
Publicado: (2002)

Efficacy of Carvedilol in Patients with Dilated Cardiomyopathy due to Beta-thalassemia major; a Double-blind Randomized Controlled Trial
por: Ajami, Gholam-Hossein, et al.
Publicado: (2010)

Plasma Zinc Level in Hepatitis C Patients With or Without Beta Thalassemia Major; Is There Any Difference?
por: Abbasinazari, Mohammad, et al.
Publicado: (2013)

Economic burden of beta-thalassemia/Hb E and beta-thalassemia major in Thai children
por: Riewpaiboon, Arthorn, et al.
Publicado: (2010)

Serum ferritin levels, socio-demographic factors and desferrioxamine therapy in multi-transfused thalassemia major patients at a government tertiary care hospital of Karachi, Pakistan
por: Riaz, Haris, et al.
Publicado: (2011)

A cross-sectional study of metabolic and endocrine complications in beta-thalassemia major
por: Najafipour, Farzad, et al.
Publicado: (2008)

MRI prospective survey on cardiac and hepatic iron in transfusion-dependent thalassemia intermedia patients treated with desferrioxamine, deferiprone and deferasirox
por: Meloni, Antonella, et al.
Publicado: (2015)

Coronavirus Disease 2019 (COVID-19) Severity in Patients with Thalassemias: A Nationwide Iranian Experience
por: Karimi, Mehran, et al.
Publicado: (2021)

Comparison of iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and deferiprone on liver and cardiac T2* MRI in thalassemia maior
por: Ansari, Shahla, et al.
Publicado: (2017)

Immunity to tetanus in major beta thalassemia patients
por: Jahromi, Abdolreza Sotoodeh, et al.
Publicado: (2015)

Watershed Infarct in Beta-Thalassemia Major Patient
por: Ansari, Behnaz, et al.
Publicado: (2017)

Epidemiology and treatment of beta thalassemia major in China
por: Xu, Xiaoxiao, et al.
Publicado: (2019)

Cutaneous Manifestations in Patients with Beta-Thalassemia Major
por: Zulfiqar, Zunaira, et al.
Publicado: (2023)

Red Blood Cell Immunization and Contributing Factors in 685 Thalassemia Patients
por: Shaiegan, Mojgan, et al.
Publicado: (2022)

A prospective MRI study of left ventricular iron and function in non-trasfusion-dependent thalassemia intermedia patients treated with desferrioxamine
por: Meloni, Antonella, et al.
Publicado: (2015)

Soy Isoflavones Supplementation for Patients with Irritable Bowel Syndrome: A Randomized Double Blind Clinical Trial
por: Jalili, Mahsa, et al.
Publicado: (2015)

Blood group genotyping in alloimmunized multi‐transfused thalassemia patients from Iran
por: Sarihi, Reyhaneh, et al.
Publicado: (2021)

Alpha thalassemia deletions found in suspected cases of beta thalassemia major in Pakistani population
por: Shahid, Saba, et al.
Publicado: (2017)

Zinc and Copper Status in Children with Beta-Thalassemia Major
por: Mahyar, Abolfazl, et al.
Publicado: (2010)

Frequency of Celiac Disease in Children with Beta Thalassemia major
por: Honar, N, et al.
Publicado: (2014)

Genetic Variation Impacts in Patients with Major Beta-Thalassemia
por: NAJAF POUR, Maliheh, et al.
Publicado: (2015)

Current and future alternative therapies for beta-thalassemia major
por: de Dreuzy, Edouard, et al.
Publicado: (2016)

Desferrioxamine Reduces Oxidative Stress in the Lung Contusion
por: Basaran, Umit Nusret, et al.
Publicado: (2013)

Desferrioxamine decreases NAD redox potential of intact red blood cells: evidence for desferrioxamine as an inducer of oxidant stress in red blood cells
por: Niihara, Yutaka, et al.
Publicado: (2002)

Liver Enzymes in Children with beta-Thalassemia Major: Correlation with Iron Overload and Viral Hepatitis
por: Salama, Khaled M., et al.
Publicado: (2015)

Beta-thalassemia
por: Galanello, Renzo, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_oruncq40cd37ms078svnm8439v